GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » Ventas Inc (NYSE:VTR) » Definitions » COGS-to-Revenue

VTR (Ventas) COGS-to-Revenue : 0.58 (As of Mar. 2025)


View and export this data going back to 1994. Start your Free Trial

What is Ventas COGS-to-Revenue?

Ventas's Cost of Goods Sold for the three months ended in Mar. 2025 was $786 Mil. Its Revenue for the three months ended in Mar. 2025 was $1,358 Mil.

Ventas's COGS to Revenue for the three months ended in Mar. 2025 was 0.58.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ventas's Gross Margin % for the three months ended in Mar. 2025 was 42.15%.


Ventas COGS-to-Revenue Historical Data

The historical data trend for Ventas's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventas COGS-to-Revenue Chart

Ventas Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.55 0.55 0.57 0.57

Ventas Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.57 0.58 0.58 0.58

Ventas COGS-to-Revenue Calculation

Ventas's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2827.069 / 4924.266
=0.57

Ventas's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=785.709 / 1358.074
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ventas  (NYSE:VTR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ventas's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 785.709 / 1358.074
=42.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Ventas COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ventas's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ventas Business Description

Traded in Other Exchanges
Address
300 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60654
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Executives
Robert F Probst officer: EVP, CFO and Acting CAO 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Walter C Rakowich director 14100 E 35TH PL, AURORA CO 80011
Debra A Cafaro director, officer: Chairman, President and CEO 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Gregory R Liebbe officer: SVP, Chief Accounting Officer 500 N. HURSTBOURNE PARKWAY, SUITE 200, LOUISVILLE KY 40222
Peter J. Bulgarelli officer: Pres&CEO-LHS/EVP Office-Ventas 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Sumit Roy director 600 LA TERRAZA BOULEVARD, ESCONDIDO CA 92025
Michael J Embler director C/O NMI HOLDINGS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Robert D. Reed director 47 DONALD DRIVE, ORINDA CA 94563
James D Shelton director 3901 TURTLE CREEK BLVD. #12, DALLAS TX 75219
Richard I Gilchrist director 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Maurice S Smith director 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
Marguerite M Nader director 2S601 AVENUE LA TOURS, OAK BROOK IL 60523
Carey S. Roberts officer: EVP and GC C/O VENTAS, INC., 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
James Justin Hutchens officer: EVP Sr Housing North America C/O VENTAS, INC., 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654
John D. Cobb officer: SVP & Chief Investment Officer 353 N. CLARK STREET, SUITE 3300, CHICAGO IL 60654